Elite in Leukemia

Dr. Harry P. Erba

Duke Health Integrated Practice Inc
Durham, NC
Elite
in Leukemia
Specialties:Oncology | Hematology | Hematology Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Harry Erba is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Erba and is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Erba is currently accepting new patients.

His clinical research consists of co-authoring 131 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 118 articles and participated in 15 clinical trials in the study of Leukemia.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Duke Regional Hospital
Sovah Health Danville
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana
  •  Piedmont

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
234 Crooked Creek Pkwy, Durham, NC 27713
919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, IMGN632, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Procedure, Drug
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Biological, Drug
Study Drugs: HDM201, MBG453, Venetoclax
Study Phase: Phase 1
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2024
Intervention Type: Drug
Study Drugs: Sabatolimab, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Drug
Study Drugs: Cytarabine, Vosaroxin
Study Phase: Phase 2
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug
Study Drugs: Cytarabine, Idarubicin, Pravastatin
Study Phase: Phase 2
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Drug: PTC299
Study Phase: Phase 1
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: May 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

130 Total Publications

A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study.
A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study.
Journal: Future oncology (London, England)
Published: December 04, 2024
Similar Doctors
Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology
Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (6.8 mi)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Stephens is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Stephens and is rated as an Elite provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Stephens is currently accepting new patients.

Expertise in
12
conditions
Dr. Joshua F. Zeidner
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Joshua F. Zeidner
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (6.8 mi)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joshua Zeidner is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Zeidner and is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Zeidner is currently accepting new patients.

Expertise in
15
conditions
Dr. Thomas W. Leblanc
Oncology | Hematology Oncology
Expertise in
15
conditions
Dr. Thomas W. Leblanc
Oncology | Hematology Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (6.6 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Leblanc is an Oncologist and a Hematologist Oncology provider in Durham, North Carolina. Dr. Leblanc and is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Leblanc is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile